The iPSCs Manufacturing Services Market Size is valued at USD 1,193.3 million in 2023 and is predicted to reach USD 2,994.6 million by the year 2031 at a 12.54 % CAGR during the forecast period for 2024-2031.
Global iPSCs Manufacturing Services Market 2025-2034 full Research Repot latest version is now available.
Get Free Access to Demo Report, Excel Pivot and ToC: https://www.insightaceanalytic.com/request-sample/1223
Induced pluripotent stem cells (iPSCs) are a variety of stem cells produced by reprogramming adult cells to transform into an embryonic-like state. In this procedure, specific genes or proteins are introduced to adult cells, such as skin or blood cells, to restore their potential to differentiate into any type of cell in the body (a characteristic referred to as pluripotency). iPSC offers a number of benefits over other forms of stem cells when it comes to regenerative medicine and wound healing models.
Since induced pluripotent stem cells (iPS cells) have a high therapeutic potential, market growth drivers include an increase in research on customized or precise medicine as well as expanded uses in regenerative treatments and therapies. Automated platforms will be used in the production of induced pluripotent stem cells (iPS cells), which will result in a decrease in costs and an increase in output. Nevertheless, the creation of induced pluripotent stem cells will be influenced by a number of primary obstacles in stem cell research, including tumorigenicity, immunological rejection, phenotypic heterogeneity of therapeutic cell products, and genetic instability.
List of Major Players in the IPSCs Manufacturing Services Market:
Cynata Therapeutics Limited,
Evotec SE,
Axol Bioscience Ltd.,
FUJIFILM Cellular Dynamics, Inc.,
Pluristyx, Inc.,
Ncardia,
I Peace Inc.,
Lonza Group AG,
Celogics Inc,
Catalent, Inc,
CCRM,
Takara Bio Inc,
Applied StemCell Inc. (ASC),
RoslinCT,
Thermo Fisher Scientific, Inc,
Expert Knowledge, Just a Click Away: https://calendly.com/insightaceanalytic/30min?month=2025-02
Market Dynamics:
Drivers-
Intracellular stem cells (iPSCs) have the potential to develop patient-specific cell lines, which would allow for individualized therapies and treatments that are tuned to the genetic profiles of particular patients. An increasing interest in precision medicine is driving the demand for disease modelling and therapeutic development that is based on iPSCs. The use of these cells as physiologically appropriate models for drug screening provides a human cell-based platform that, in comparison to animal models, more accurately predicts how humans will react to various chemicals.
Pharmaceutical firms are investing in iPSC technology because it speeds up the timetables for drug discovery and reduces the expenses associated with failures in later stages of the drug development process.
Challenges:
The manufacturing and use of induced pluripotent stem cells (iPSCs) are linked to significant expenses. It includes the expenses for specialized equipment, chemicals, and highly skilled staff required for the production process. Implementing iPSC-based treatments widely in clinical settings might be difficult because of the exorbitant expenses, which limit their availability and affordability. In addition, the intricacy of production procedures is a significant obstacle in this industry.
The manufacturing process for induced pluripotent stem cells (iPSCs) is complex and requires careful regulation of many stages, including reprogramming, growth, and differentiation. The degree of intricacy at this level requires a considerable amount of knowledge and a meticulous focus on aspects which might need a significant allocation of resources. The manufacturing process is further complicated by the need for specialized reagents and equipment, leading to higher prices and possible production bottlenecks.
Regional Trends:
It is anticipated that the North American iPSCs Manufacturing Services market will exhibit a significant market share in terms of revenue and is expected to expand at a high CAGR in the near future. Rapid advancements in research on neuropathies, cardiac diseases, and personalized medicine in North America are significant growth drivers. Substantial funding and investments are directed toward advancing iPSC manufacturing technologies in the region.
Besides, the Europe region had a considerable market share due to the region’s supportive regulatory environment and robust healthcare infrastructure. Furthermore, the market’s growth is further stimulated by the collaborative endeavours of industry participants and academic institutions, which enhance research and development activities.
Unlock Your GTM Strategy: https://www.insightaceanalytic.com/customisation/1223
Recent Developments:
In Dec 2023, FUJIFILM Corporation declared a USD 200 million investment in two companies to substantially enhance worldwide cell therapy contract development and manufacturing (CDMO) capabilities. The investment would allow Fujifilm to facilitate the burgeoning cell treatment business, which is projected to increase by over 30% annually from USD 3.3 billion in FY2022. The $200 million investment in cell therapy manufacturing capabilities is designated for the new headquarters of FUJIFILM Cellular Dynamics, Inc., a prominent global developer & manufacturer of iPSC and iPSC-derived cells, as well as the California facility of FUJIFILM Diosynth Biotechnologies.
Segmentation of IPSCs Manufacturing Services Market-
By Applications-
Research Products
Drug Development & Discovery
Cellular Therapy
Toxicology Screening
Personalized Medicine
Disease Modelling
Stem Cell Banking
Emerging Applications
By End-user-
Pharmaceutical & Biotechnology Companies
Academic institutes, Research Laboratories & CROs
Hospitals & Surgical Centres
Cell & Tissue Banks
Other End Users
By Service Type-
iPSCs Generation
iPSCs Differentiation
iPSCs Characterization and Quality Control
iPSCs Banking
Others
By Region-
North America-
The US
Canada
Mexico
Europe-
Germany
The UK
France
Italy
Spain
Rest of Europe
Asia-Pacific-
China
Japan
India
South Korea
South East Asia
Rest of Asia Pacific
Latin America-
Brazil
Argentina
Rest of Latin America
Middle East & Africa-
GCC Countries
South Africa
Rest of Middle East and Africa
About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.
Contact us:
InsightAce Analytic Pvt. Ltd.
Visit: www.insightaceanalytic.com
Tel : +1 551 226 6109
Asia: +91 79 72967118
info@insightaceanalytic.com
